HC Wainwright Trims Altimmune (NASDAQ:ALT) Target Price to $12.00

Altimmune (NASDAQ:ALT - Free Report) had its price target decreased by HC Wainwright from $15.00 to $12.00 in a research note published on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other equities research analysts also recently issued research reports about the stock. The Goldman Sachs Group began coverage on shares of Altimmune in a research note on Wednesday, January 24th. They set a neutral rating and a $13.00 target price for the company. B. Riley reiterated a buy rating and set a $20.00 target price on shares of Altimmune in a research note on Thursday.

Altimmune Stock Performance

Shares of ALT stock traded up $0.05 during mid-day trading on Monday, hitting $10.23. 5,080,956 shares of the stock were exchanged, compared to its average volume of 6,050,458. The stock's fifty day simple moving average is $9.93 and its two-hundred day simple moving average is $6.88. The stock has a market capitalization of $549.66 million, a price-to-earnings ratio of -6.20 and a beta of 0.05. Altimmune has a 12-month low of $2.09 and a 12-month high of $14.84.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ALT. Osaic Holdings Inc. raised its position in shares of Altimmune by 77.3% during the 2nd quarter. Osaic Holdings Inc. now owns 7,834 shares of the company's stock worth $28,000 after purchasing an additional 3,416 shares during the last quarter. WealthPlan Investment Management LLC acquired a new position in shares of Altimmune during the 3rd quarter worth approximately $31,000. FNY Investment Advisers LLC acquired a new position in shares of Altimmune during the 4th quarter worth approximately $35,000. Keudell Morrison Wealth Management acquired a new position in Altimmune in the 3rd quarter valued at $36,000. Finally, Brave Asset Management Inc. acquired a new position in Altimmune in the 3rd quarter valued at $39,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.